Navigation Links
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Date:12/12/2012

ons that indicate future events and trends.

All statements that address expectations or projections about the future, including, without limitation, statements about product launches, governmental and regulatory actions and proceedings, market position, revenues, expenditures and the impact of recalls and suspensions of shipments on revenues, adjustments to the financial statements, the filing of amended filings with the Securities and Exchange Commission ("SEC") and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, we provide the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. Such factors include (but are not limited to): (1) the ability of the Company and its subsidiaries to continue as a going concern; (2) the risk that the Bankruptcy Court will not approve the Hologic Settlement; (3) the risk that the Bankruptcy Court will not approve the Company's entry into the currently proposed DIP financing facility, which is required to fund the Hologic Settlement ; (4) the ability of the Company and its subsidiaries to obtain Bankruptcy Court approval with respect to other motions in the Chapter 11 cases; (5) the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 cases; (6) the effects of the bankruptcy filing on the Company and its subsidiaries and the interests of various creditors, equity holders and other constituents; (7) the effects of rulings of the Bankruptcy Court in the Chapter 11 cases and the outcome of the cases in general; (8) the lengt
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... MD (PRWEB) May 05, 2015 RURO, ... provider released FreezerPro® version 7, the latest major content ... software., Upgrade is a significant ... UI succeeds in enhancing users experience, while also simplifying ... performance, reduces system requirements , Download available ...
(Date:5/5/2015)... AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. ... reported financial results for the three months ended March ... otherwise, all amounts are in Canadian dollars. ... fiscal year end from May 31 to December 31. ... period being reported is for the three months ended ...
(Date:5/5/2015)... Calif. , May 5, 2015  23andMe, Inc., ... of the Lupus Research Study in collaboration ... individuals with systemic lupus erythematosus, more commonly known as ... genetics of lupus. The effort is also in collaboration ... Lupus Awareness Month in May. Approximately 1.5 ...
(Date:5/5/2015)... 05, 2015 Hayden-McNeil is ... develop custom course materials for smaller courses. This program ... low as 200 students. , “I’m very excited ... of higher education instructors,” said Jeff McCarthy, Hayden-McNeil president. ... can do our part to make education both more ...
Breaking Biology Technology:RURO Releases version 7 of FreezerPro® software 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 823andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2
... 15 /PRNewswire-Asia-FirstCall/ -- China Integrated,Energy, Inc. (Nasdaq: CBEH ; ... announced its selected unaudited,preliminary financial results for the third quarter ... sales to be at least $71 million and net income ... 4.4%,respectively, compared to the third quarter of 2008. , ...
... , BRIARCLIFF MANOR, N.Y., Oct. 15 The mission ... is to advance the medical publication profession through education ... growing misperceptions in the medical literature and lay press ... such as the perception that all medical writing is ...
... Cytochroma today announced that it has appointed John Cunningham, ... Advisory Board. , Dr. Cunningham is Professor of Nephrology ... at the Royal Free Hospital, London. His early training ... in The University of London and Washington University ...
Cached Biology Technology:China Integrated Energy, Inc. Announces Preliminary Third Quarter Financial Results and Increases Full Year Guidance 2ISMPP Supports Best Practices and Transparency in Medical Publications: Better Understanding of Terms Such as 'Ghostwriting' Needed 2ISMPP Supports Best Practices and Transparency in Medical Publications: Better Understanding of Terms Such as 'Ghostwriting' Needed 3Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 2Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 3
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... ?one from Louisiana, one from Japan and one ... to involvement of endocannabinoids as a novel neural ... in eating, disease treatment and social behavior. , ... team from Tulane and Louisiana State Universities, led ...
... as fertility drugs may be ineffective for women who ... study showed that fertility drugs did not improve ovulation ... estrogen receptor beta. The estrogen receptor beta is one ... of estrogen hormones and are present throughout the female ...
... extension in yeast have been identified by researchers from UC ... or caloric restriction, is known to extend the lifespan of ... gene called Sir2 with lifespan extension due to caloric restriction, ... when put on a tough diet, showing that some other ...
Cached Biology News:Endocannabinoids ?the brain's cannabis ?demonstrate novel modes of action to stress 2New Discovery May Help Doctors Treat Infertility 2New Discovery May Help Doctors Treat Infertility 3
Human/Mouse/Rat LAR Affinity Purified PAb...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Human Jagged 2 Biotinylated Affinity Purified PAb...
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)...
Biology Products: